Related Experiment Video

Updated: Jul 12, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data

Vlado Perkovic1, Toshiharu Ninomiya, Hisatomi Arima

  • 1George Institute for International Health, PO Box M201, Sydney, Australia, 2050. vperkovic@thegeorgeinstitute.org

Journal of the American Society of Nephrology : JASN
|September 7, 2007
PubMed

Insights

Patients with chronic kidney disease (CKD) face higher cardiovascular risks. Perindopril significantly reduced major vascular events and stroke in CKD patients, highlighting the importance of kidney function in treatment decisions.

Area of Science:

  • Nephrology
  • Cardiology
  • Neurology

Background:

  • Chronic kidney disease (CKD) significantly elevates cardiovascular disease (CVD) risk.
  • Limited evidence exists on effective interventions to mitigate CVD risk in CKD patients.

Purpose of the Study:

  • To evaluate the effectiveness of perindopril-based blood pressure-lowering therapy in reducing vascular events in patients with cerebrovascular disease, particularly those with CKD.

Main Methods:

  • The Perindopril Protection against Recurrent Stroke Study (PROGRESS) involved 6105 participants with cerebrovascular disease.
  • Participants were randomized to perindopril-based therapy or placebo.
  • Subgroup analysis focused on individuals with CKD.

Main Results:

  • CKD patients had a 1.5-fold higher risk of major vascular events, stroke, and coronary heart disease, and over double the mortality risk (P<=0.002).
  • Perindopril therapy reduced major vascular events by 30% and stroke by 35% in CKD patients.
  • Absolute treatment benefits were 1.7 times greater in CKD patients compared to non-CKD patients.

Conclusions:

  • Perindopril effectively reduced vascular events in patients with CKD and cerebrovascular disease.
  • Treatment prevented one major event for every 11 CKD patients treated with perindopril over five years.
  • Kidney function assessment is crucial for guiding blood pressure-lowering therapy decisions in patients with cerebrovascular disease.

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...